Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2010, Article ID 328316, 3 pages
Case Report

Sweet Syndrome due to Myelodysplastic Syndrome: Possible Therapeutic Role of Intravenous Immunoglobulin in Addition to Standard Treatment

1Division of Haematology, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong
2Department of Pathology, Queen Mary Hospital, Pokfulam, Hong Kong
3Division of Dermatology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong

Received 8 July 2009; Revised 12 October 2009; Accepted 2 February 2010

Academic Editor: Peter A. Jacobs

Copyright © 2010 Harry H. S. Gill et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


We report an 82-year-old lady who developed sudden onset nodular and erythematous lesions and neutrophilia following an episode of urinary tract infection. Skin biopsy confirmed the diagnosis of Sweet syndrome. Response to the use of prednisolone alone was not satisfactory. The skin lesions however showed a sustained response to the regular use of intravenous immunoglobulin (IVIG) and prednisolone was slowly weaned off. Our case highlights the possible therapeutic role of IVIG in managing this condition.